Table S1. Quality assessment of cohort studies.

	Selection				Comparability	Outcomes		
Reference	**Representative of Exposed Studies** [A]	**Selection of Non-Exposed** [B]	**Ascertainment of Exposure** [C]	**Demonstration of Outcome** [D]	**Comparability of Cohort Studies on Basis of Design** [E]	**Assessment of Outcomes** [F]	**Adequacy of Follow-Up** [G]	**Quality Score**
Peng et al., 2000 [1]	*	*	*	*	*	*	*	7
Shelton et al., 2011 [2]	*	*	*	*	*	*	*	7
Ishizuka et al., 2012 [3]	*	*	*	*	*	*	*	7
Toyama et al., 2017 [4]	*	*	*	*	*	-	*	6
Englund et al., 1990 [5]	*	*	*	*	*	*	*	7
Linn et al., 1995 [6]	*	*	*	*	*	*	*	7

A: *=truly representative or somewhat representative of average in target population. B: *=Drawn from the same community. C: *=Secured record or structured review. D: *=Yes, - = No. E: *= Study controls for age, gender, and other factors. F: *=Record linkage or blind assessment, **=Both. G: *=follow-up of all subjects.

Table S2. Risk of bias assessment for randomized controlled trials.

Study	**Random Sequence Generation**	**Allocation Concealment**	**Blinding of Participants and Personnel**	**Blinding of Outcome Assessment**	**Incomplete Outcome Data**	**Selective Reporting**	**Other Bias**
Cass et al., 1999 [7]	Low risk	Low risk	Unclear	Low risk	Low risk	Low risk	Unclear
Weller et al., 2013 [8]	Low risk	Low risk	High risk	High risk	Low risk	Low risk	Unclear
Cass et al., 1999 [9]	Low risk	Low risk	Unclear	Low risk	Low risk	Low risk	Unclear
Peng et al., 2000 [10]	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear
Ishizuka et al., 2011 [11]	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear
Ishizuka et al.,2010 [12]	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear
Yoshiba et al., 2011 [13]	Low risk	Low risk	Unclear	Unclear	Low risk	Low risk	Unclear
Yoshihara et al., 2013 [14]	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear
Couroux et al., 2022 [15]	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Unclear
Dumont et al., 2020 [16]	Low risk	Low risk	Low risk	Low risk	Unclear	Low risk	Unclear
Atmar et al., 1990 [17]	Low risk	Low risk	High risk	High risk	Low risk	Low risk	Unclear

References

1. Peng, A.W.; Hussey, E.K.; Rosolowski, B.; Blumer, J.L. Pharmacokinetics and tolerability of a single inhaled dose of zanamivir in children. *Curr. Ther. Res.* **2000**, *61*, 36–46.
2. Shelton, M.J.; Lovern, M.; Ng-Cashin, J.; Jones, L.; Gould, E.; Gauvin, J.; Rodvold, K.A. Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. *Antimicrob. Agents Chemother.* **2011**, *55*, 5178–5184. https://doi.org/10.1128/aac.00703-11.
3. Ishizuka, H.; Toyama, K.; Yoshiba, S.; Okabe, H.; Furuie, H. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers. *Antimicrob. Agents Chemother.* **2012**, *56*, 3873–3878.
4. Toyama, K.; Furuie, H.; Ishizuka, H. Safety and Pharmacokinetics of Nebulized Laninamivir Octanoate, A Long Acting Neuraminidase Inhibitor, In Healthy Subjects. *Clin. Ther.* **2017**, *39*, e25–e26.
5. Englund, J.A.; Piedra, P.A.; Jefferson, L.S.; Wilson, S.Z.; Taber, L.H.; Gilbert, B.E. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. *J. Pediatr.* **1990**, *117*, 313–320.
6. Linn, W.S.; Gong, H.; Anderson, K.R.; Clark, K.W.; Shamoo, D.A. Exposures of Health-Care Workers to Ribavirin Aerosol: A Pharmacokinetic Study. *Arch. Environ. Health: Int. J.* **1995**, *50*, 445–451. https://doi.org/10.1080/00039896.1995.9935981.
7. Cass, L.M.R.; Efthymiopoulos, C.; Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. *Clin. Pharmacokinet.* **1999**, *36*, 1–11.
8. Weller, S.; Jones, L.S.; Lou, Y.; Piscitelli, S.; Peppercorn, A.; Ng-Cashin, J. *Safety, Tolerability and Pharmacokinetics of Orally inhaled Zanamivir: A Randomized Study Comparing Rotacap/Rotahaler and Rotadisk/Diskhaler in Healthy Adults*; SAGE Publications Sage UK: London,UK, 2013.
9. Cass, L.M.R.; Brown, J.; Pickford, M.; Fayinka, S.; Newman, S.P.; Johansson, C.J.; Bye, A. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. *Clin. Pharmacokinet.* **1999**, *36*, 21–31.
10. Peng, A.W.; Hussey, E.K.; Moore, K.H.P. A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: Effects of formulation and route of administration. *J. Clin. Pharmacol.* **2000**, *40*, 242–249.
11. Ishizuka, H.; Yoshiba, S.; Yoshihara, K.; Okabe, H. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958. *J. Clin. Pharmacol.* **2011**, *51*, 243–251.
12. Ishizuka, H.; Yoshiba, S.; Okabe, H.; Yoshihara, K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. *J. Clin. Pharmacol.* **2010**, *50*, 1319–1329.
13. Yoshiba, S.; Okabe, H.; Ishizuka, H. Pharmacokinetics of laninamivir after a single administration of its prodrug, laninamivir octanoate, a long-acting neuraminidase inhibitor, using an easy-to-use inhaler in healthy volunteers. *J. Bioequiv. Availab.* **2011**, *3*, 001–004.
14. Yoshihara, K.; Ishizuka, H.; Kubo, Y. Population Pharmacokinetics of Laninamivir and Its Prodrug Laninamivir Octanoate in Healthy Subjects and in Adult and Pediatric Patients with Influenza Virus Infection. *Drug Metab. Pharmacokinet.* **2013**, *28*, 416–426. https://doi.org/10.2133/dmpk.DMPK-12-RG-115.
15. Couroux, P.; Brkovic, A.; Vittitow, J.L.; Israel, R.J.; Pamidi, C.; Patel, J.; Barakat, M. A randomized, placebo-controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin. *Clin. Transl. Sci.* **2022**, *15*, 2159–2171.
16. Dumont, E.F.; Oliver, A.J.; Ioannou, C.; Billiard, J.; Dennison, J.; Van Den Berg, F.; Yang, S.; Chandrasekaran, V.; Young, G.C.; Lahiry, A. A novel inhaled dry-powder formulation of ribavirin allows for efficient lung delivery in healthy participants and those with chronic obstructive pulmonary disease in a phase 1 study. *Antimicrob. Agents Chemother.* **2020**, *64*, e02267-02219.
17. Atmar, R.L.; Greenberg, S.B.; Quarles, J.M.; Wilson, S.Z.; Tyler, B.; Feldman, S.; Couch, R.B. Safety and pharmacokinetics of rimantadine small-particle aerosol. *Antimicrob. Agents Chemother.* **1990**, *34*, 2228–2233.